ReviewGut2011
Colorectal cancer molecular biology moves into clinical practice.
Review in Gut, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 2 syntheses or guidelines pooled it, 352 citations in OpenAlex.
- Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.The oncologist · 2023Pooled it
- Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Guideline
- Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer.World journal of surgical oncology · 2015Trial
- CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Gastroenterology · 2014Trial
- Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.Japanese journal of clinical oncology · 2014Trial
- Trial
- Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012Trial
- Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- The Galectin Family in Colorectal Cancer: Integrating Molecular Mechanisms with Diagnostic, Prognostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- Review
- Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASSignal transduction and targeted therapy · 2025Article
- Genistein potentiated the cytotoxic effect of entinostat in colorectal cancer cell lines.Research in pharmaceutical sciences · 2025Article
- Deep learning for fine-grained molecular-based colorectal cancer classification.Translational cancer research · 2025Article
- Article
- The role of UGT1A1 polymorphism in the management of colorectal cancer.Oncology reviews · 2025Review
- Predictive role of [EJNMMI reports · 2024Article
- Functions of Circular RNA in Human Diseases and Illnesses.Non-coding RNA · 2023Review
- Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.International journal of molecular sciences · 2023Review
- Comprehension of rectosigmoid junction cancer molecular features by comparison to the rectum or sigmoid colon cancer.Journal of gastrointestinal oncology · 2023Article
- CircRNAs in colorectal cancer: potential biomarkers and therapeutic targets.Cell death & disease · 2023Review
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next major advance in clinical medicine. This is no more evident than in the recent advances in testing of colorectal cancers for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, genetic mechanisms of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers) are examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.